In metabolic disorders, GDF-15’s association with subclinical atherosclerosis was present, but inconsistent, since this association tended to be stronger in patients with advanced metabolic disturbances, and weaker in younger patients or those with better metabolic control [17,20,34]. Here, GDF15 is linked to metabolic disease.